Ambrx Appoints Barry Greene to Board of Directors

              Ambrx Appoints Barry Greene to Board of Directors

PR Newswire

SAN DIEGO, Feb. 5, 2014

SAN DIEGO, Feb. 5, 2014 /PRNewswire/ --Ambrx Inc. today announced the
appointment of Barry Greene to its board of directors. Mr. Greene has more
than 20 years of experience in the healthcare, pharmaceutical and
biotechnology industries. He is currently president and chief operating
officer of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), a leader in RNAi
therapeutics. The appointment increases Ambrx's board membership to six.

"Barry joins Ambrx's board at a very exciting time for the company with our
continued development of a robust pipeline and establishment of collaborations
with pharmaceutical and biotech companies worldwide, including those in the
emerging Chinese market," said Lawson Macartney, Ph.D., chief executive
officer of Ambrx. "Barry's expertise in strategy and operations with growth
companies will be a welcome addition by our directors and company executives.
Our position is to build the most dominant, diverse pipeline of
biotherapeutics, including antibody-drug conjugates (ADCs) with the most
advanced set of technology tools, including our Protein Medicinal Chemistry™."

Prior to joining Alnylam in 2003, Mr. Greene was general manager of oncology
at Millennium Pharmaceuticals Inc. He focused on global strategy and execution
for Millennium's oncology business to guide near- and long-term research,
development and commercialization and was involved in the successful approval
and launch of VELCADE® (bortezomib). Earlier, he was vice president of
strategic integration with responsibility for the AstraZeneca North America
post-merger integration and vice president of marketing and customer services
for AstraZeneca. Prior to his work with AstraZeneca, he was a partner with
Andersen Consulting, where he was responsible for the pharmaceutical and
biotechnology marketing and sales practice. Mr. Greene holds a bachelor of
science degree in industrial engineering from the University of Pittsburgh.

About Ambrx
Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded
genetic code to create best-in-class biotherapeutics, including ADCs,
bispecific antibodies and proteins with improved pharmacologic properties. The
company is developing ARX201, a long-acting growth hormone that has
successfully completed Phase 2b clinical trials. In addition to its most
recent ADC collaborations with Merck, Astellas and Bristol-Myers Squibb, Ambrx
has collaborations to discover and develop products incorporating Ambrx
technology with Bristol-Myers Squibb, Eli Lilly and several undisclosed
companies. Ambrx is advancing a robust portfolio of product candidates that
are optimized for efficacy, safety and ease of use in multiple therapeutic
areas.

For additional information, visit www.ambrx.com

Media Contact:
David Schull
(212) 845-4271
david.schull@russopartnersllc.com

SOURCE Ambrx Inc.

Website: http://www.ambrx.com
 
Press spacebar to pause and continue. Press esc to stop.